Danazol for paroxysmal nocturnal hemoglobinuria
review
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
Danazol therapy improved hematocrit and reduced transfusion needs in four of five patients with paroxysmal nocturnal hemoglobinuria refractory to other treatments.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted > or =2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (30)
- An apparent danazol‐induced primary hepatocellular carcinoma: Case report via openalex
- Danazol for Lupus Thrombocytopenia via openalex
- Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases via openalex
- Danazol Therapy for Autoimmune Hemolytic Anemia via openalex
- Danazol therapy renders red cells resistant to osmotic lysis <sup>1</sup> via openalex
- Efficacy of Danazol in Hematologic Disorders via openalex
- Hepatosplenic Peliosis after Danazol and Glucocorticoids for ITP via openalex
- High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. via openalex
- doi:10.1097/00005792-196609000-00001 via openalex
- doi:10.1056/nejm198306093082306 via openalex
- doi:10.1056/nejm197612232952602 via openalex
- doi:10.1056/nejm198702263160903 via openalex
- doi:10.1007/978-1-59259-963-9_86 via openalex
- doi:10.1016/0090-1229(87)90016-x via openalex
- doi:10.2169/internalmedicine1962.29.417 via openalex
- doi:10.1007/bf00320896 via openalex
- doi:10.1016/0002-9378(81)90611-6 via openalex
- doi:10.1056/nejm199511093331904 via openalex
- doi:10.1182/blood.v66.6.1247.1247 via openalex
- doi:10.1111/j.1365-2249.1991.tb06205.x via openalex
- doi:10.1182/blood.v86.9.3277.bloodjournal8693277 via openalex
- doi:10.7326/0003-4819-114-11-997_4 via openalex
- doi:10.1111/j.1600-0609.1975.tb00299.x via openalex
- doi:10.1182/blood.v60.1.20.20 via openalex
- doi:10.1182/blood.v64.1.253.253 via openalex
- doi:10.1136/jcp.44.8.704-a via openalex
- doi:10.1007/bf01837366 via openalex
- doi:10.1002/ajh.2830500306 via openalex
- doi:10.7326/0003-4819-84-6-692 via openalex
- doi:10.1002/ajh.2830250108 via openalex
Cited by (3)
- Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria 2013
- Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis 2010
- Monitoring of CD59 expression in paroxysmal nocturnal hemoglobinuria treated with danazol 2001
Source provenance
- openalex
- last seen: 2026-05-14T06:02:11.780192+00:00
- unpaywall
- last seen: 2026-10-08T06:33:43.470499+00:00
License: CC0
· commercial use OK